- Starting April 1st,
Company's virtual consultation service gives patients access to
clinic services and doctors trained to prescribe medical
cannabis
- Teleconsultation service anticipated to quickly expand to meet
potential growing demand for telehealth services, including
Company's 120,000 patients from its ILANS and Zerenia clinics
- Khrion has already received initial approvals from third party
payers to include teleconsultation services in its insured service
offerings
- Khiron and its clinics continue to be operational during
COVID-19 pandemic under an exemption decreed by the Government of
Colombia, without any requirement
for further authorization
- Virtual medical services complement Khiron's delivery service
that is already successfully delivering prescriptions directly to
patients' homes
- Telemedicine acceptance increasing rapidly, with average US
compound visit growth of 52% per year from 2005 – 2014 (Source:
JAMA)
- Khiron is the first company authorized to sell medical cannabis
in Colombia
TORONTO, March 30, 2020 /CNW/ - Khiron Life Sciences Corp.
("Khiron" or the "Company") (TSXV: KHRN), (OTCQX: KHRNF),
(Frankfurt: A2JMZC), a vertically
integrated cannabis leader with core operations in Latin America, today announced the Company has
launched its teleconsultation services, leveraging its medical team
and existing patient network to meet essential patient needs during
the current COVID-19 pandemic. From an initial beta launch, the
Company anticipates rapidly expanding services across its entire
patient network amidst the growing acceptance of telemedicine
services.
"We are in unprecedented times and so it is more important than
ever for Khiron to continue to meet the medical needs of our
patients. The launch of our teleconsultation services was made
possible with our on-staff doctor expertise and established patient
network, allowing us to move swiftly to continue to deliver
clinical services and prescriptions for medical cannabis and other
drugs, directly to the patients who need it," comments
Alvaro Torres, Khiron CEO and
director.
Khiron's teleconsultation services launch on April 1st, with an initial beta phase
to serve priority patient needs. Expanded services will launch in
the coming weeks to be fully available to patients across
Colombia, including to the
Company's over 120,000 patient network established through its
ILANS and Zerenia medical facilities. The Company is working
closely with third party payers to ensure the program meets their
insurance coverage requirements.
"Khiron has established contingency plans in place for all our
facilities, including our medical facilities which are essential to
serving the community. Those plans were put into action and our
medical facilities and supply chain remain operating within strict
government guidelines established as a result of the current
pandemic. I commend our frontline staff for their continued hard
work and commitment to meeting patient needs during this difficult
time," said Mr. Torres.
Khiron is the first, and currently the only, Company
authorized to sell medical cannabis in Colombia, having recently obtained
certification of Good Elaboration Practices (GEP) for Magistral
Preparations with Cannabis. Under Colombian regulations, GEP is a
manufacturing and processing certification that is a mandatory
requirement for commercializing customized medical cannabis
prescriptions known as magistral preparations.
About Khiron Life Sciences Corp.
Khiron Life Sciences
Corp. is the dominant integrated medical cannabis company in
Latin America. Khiron has core
operations in Latin America, along
with activity in North America and
Europe, and is licensed in
Colombia for the cultivation,
production, domestic distribution, and international export of both
tetrahydrocannabinol (THC) and cannabidiol (CBD) medical cannabis.
The Company delivers best in class regulatory compliance, has the
first approved line of CBD cosmetic products on shelf
in Colombia, and is fully authorized to manufacture high- and
low-THC medical cannabis, and to fill prescriptions for low-THC
medical cannabis in the country.
With a focused regional strategy and patient oriented
approach, the Company combines global scientific expertise,
agricultural advantages, branded product market entrance
experience and education to drive prescription and brand
loyalty to address priority medical conditions such as chronic
pain, epilepsy, depression and anxiety in the Latin American
market of over 620 million people. The Company is led by Co-founder
and Chief Executive Officer, Alvaro
Torres, together with an experienced executive team,
and a knowledgeable Board of Directors that includes former
President of Mexico, Vicente Fox.
Visit Khiron online at www.khiron.ca and on Instagram
@khironlife
Cautionary Notes
Forward-Looking Statements
This press release may contain certain "forward-looking
information" and "forward-looking statements" within the meaning of
applicable securities legislation. All information contained herein
that is not historical in nature may constitute forward-looking
information. Khiron undertakes no obligation to comment analyses,
expectations or statements made by third-parties in respect of
Khiron, its securities, or financial or operating results (as
applicable). Although Khiron believes that the expectations
reflected in forward-looking statements in this press release are
reasonable, such forward-looking statement has been based on
expectations, factors and assumptions concerning future events
which may prove to be inaccurate and are subject to numerous risks
and uncertainties, certain of which are beyond Khiron's control,
including the risk factors discussed in Khiron's Annual Information
Form which is available on Khiron's SEDAR profile
at www.sedar.com. The forward-looking information contained in
this press release is expressly qualified by this cautionary
statement and are made as of the date hereof. Khiron disclaims any
intention and has no obligation or responsibility, except as
required by law, to update or revise any forward-looking
information, whether as a result of new information, future events
or otherwise.
United States Disclaimer
This news release does not constitute an offer to sell or a
solicitation of an offer to buy any of the securities
in the United States. The securities have not been and
will not be registered under the United States Securities Act of
1933, as amended (the "U.S. Securities Act") or any state
securities laws and may not be offered or sold within the
United States or to U.S. Persons
(as such term is defined in Regulation S under the U.S. Securities
Act) unless registered under the U.S. Securities Act and applicable
state securities laws or an exemption from such registration is
available
Neither the TSXV nor its Regulation Services Provider (as
that term is defined in the policies of the TSXV) accepts
responsibility for the adequacy or accuracy of this press
release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/khiron-meets-essential-patient-needs-with-launch-of-teleconsultation-services-in-colombia-301032138.html
SOURCE Khiron Life Sciences Corp.